Bayer's Ruveon Demerger Is More Than a Legal Shield – It's a Valuation Reset

Bayer spins off US glyphosate business into Ruveon LLC ahead of $7.25B Roundup settlement final hearing, sending shares up 39% year-to-date.

The countdown to a final legal reckoning has given Bayer the cover to execute a structural overhaul that investors are rewarding handsomely. On 19 August 2026, a US court will hold a final hearing to approve a $7.25 billion class-action settlement over Roundup-related claims – a milestone that has already been tentatively greenlit. But well before that date, the German conglomerate set in motion a far-reaching reorganisation of its US glyphosate operations.

The centrepiece is Ruveon LLC, a newly formed subsidiary headquartered in St. Louis, Missouri, that will house all of Bayer's glyphosate-based product sales in the United States. Alfonso Alba Ordonez has been appointed to lead the unit, which remains wholly owned by the parent. The move is part of a broader five-year restructuring programme within the agricultural division and is widely interpreted as a preparatory step for a potential partial sale or full spin-off down the road. By isolating the litigation-exposed business, Bayer hopes to ring-fence future liabilities and give investors cleaner visibility on the rest of the group's performance.

Legal momentum has been building for months. In February, Bayer secured preliminary approval for the $7.25 billion settlement. Then came a crucial victory at the US Supreme Court, which declined to hear appeals arguing that state-level cancer warnings on Roundup should supersede federal labelling standards. The justices effectively endorsed the uniformity of Environmental Protection Agency guidelines, a decision that sharply narrows the scope for future claims. Combined, these developments have lifted a cloud that had hung over the stock for years.

The market greeted the twin catalysts with enthusiasm. Shares jumped 8.58% on the day of the Ruveon announcement, reaching €52.88 and edging toward their 52-week high of €53.38. The stock has now gained nearly 39% since the start of the year and has roughly doubled over the past twelve months. Deutsche Bank’s Virginie Boucher-Ferte responded by upgrading the stock from "Hold" to "Buy" and raising her price target from €45 to €60. She argued that the long-running glyphosate litigation is losing its potency, while the restructuring unlocks a new valuation narrative.

Technicians, however, sound a note of caution. The Relative Strength Index has climbed to 85, signalling that the equity is deeply overbought in the near term. A pullback would not be unusual given the speed of the advance, but the fundamental case remains intact as long as the legal path stays clear.

All eyes now turn to the August hearing. If the settlement receives final approval, Bayer will have eliminated the biggest source of uncertainty that has suppressed its valuation for years. The Ruveon spin-off, meanwhile, provides a flexible vehicle for further corporate action – whether a full divestiture, a partnership, or simply a cleaner operational structure. Investors are betting that the combination of legal closure and structural clarity marks a genuine turning point for the stock.